今日涨跌幅居前的概念板块 截至7月23日收盘，CRO概念上涨0.43%，位居概念板块涨幅第6，板块内，35股上涨，美迪西、和元生 物、益诺思等涨幅居前，分别上涨8.83%、8.61%、7.86%。跌幅居前的有诚达药业、四川双马、谱尼测 试等，分别下跌13.12%、6.06%、3.73%。 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 603127 | 昭衍新 药 | 6.43 | 9.22 | 20301.49 | 12.72 | | 688076 | ST诺泰 | 3.72 | 8.35 | 9287.12 | 8.59 | | 000813 | 德展健 康 | 3.57 | 7.73 | 8458.92 | 13.24 | | 300347 | 泰格医 药 | 0.66 | 3.12 | 7741.24 | 7.48 | | 603538 | 美诺华 | 4.20 | 15.91 | 3839.84 | 4.36 ...

式回购公司股份 5,026,200 股，占公司目前总股本的 0.23%，具体内容详见公司 于 2024 年 9 月 4 日在巨潮资讯网（www.cninfo.com.cn）等指定信息披露媒体披 露的《关于首次回购公司股份的公告》（公告编号：2024-044）。 德展大健康股份有限公司（以下简称"公司"）分别于 2024 年 7 月 1 日及 东大会，审议并通过了《关于回购公司股份方案的议案》。基于对公司所属行业 前景的认可、对公司未来发展的信心及公司价值的判断，为进一步增强投资者信 心，稳定投资者预期，维护广大投资者的利益，公司计划自股东大会审议通过之 日起 12 个月内使用不低于人民币 2 亿元，不超过人民币 3 亿元的自有资金，通 过集中竞价交易方式以不超过人民币 3.59 元/股的价格回购股份。本次回购的股 份将全部用于注销减少公司注册资本。具体内容详见公司于 2024 年 7 月 19 日在 《证券时报》《证券日报》《上海证券报》《中国证券报》和巨潮资讯网 （www.cninfo.com.cn）披露的《回购报告书》（公告编号：2024-036）。2025 年 为"公司自有资金及金融机构借款"。 截至 ...

证券代码：000813 证券简称：德展健康 公告编号：2025-056 德展大健康股份有限公司 关于公司股份回购结果暨股份变动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 德展大健康股份有限公司（以下简称"公司"）分别于 2024 年 7 月 1 日及 2024 年 7 月 18 日召开了第八届董事会第二十七次会议和 2024 年第一次临时股 东大会，审议并通过了《关于回购公司股份方案的议案》。基于对公司所属行业 前景的认可、对公司未来发展的信心及公司价值的判断，为进一步增强投资者信 心，稳定投资者预期，维护广大投资者的利益，公司计划自股东大会审议通过之 日起 12 个月内使用不低于人民币 2 亿元，不超过人民币 3 亿元的自有资金，通 过集中竞价交易方式以不超过人民币 3.59 元/股的价格回购股份。本次回购的股 份将全部用于注销减少公司注册资本。具体内容详见公司于 2024 年 7 月 19 日在 《证券时报》《证券日报》《上海证券报》《中国证券报》和巨潮资讯网 （www.cninfo.com.cn）披露的《回购报告书》（公告编号：2024-036 ...

对此，德展健康方面表示，科技创新发展中心有利于有效集聚专家技术优势，强化内在创新驱动能力， 加速推进公司研发创新战略布局，助力实现医药行业的创新转型与升级，并为公司药品研发，特别是创 新药研发管线的推进及产业化提供坚实支撑与保障。(秦声) 据了解，近年来行业领军企业设立科技创新咨询组织，在统筹科技创新战略、长期战略投资布局、重大 项目咨询论证及科技监督评估等方面发挥着积极作用，积累了成功经验。回溯此前公告，德展健康与中 国工程院杨宝峰院士合作共建的院士工作站已经获批，需要设立专职机构，依托院士工作站平台，构建 公司科技创新的外脑支持体系，实现科技决策的科学化、专业化和前置化，有效降低创新风险，推动公 司科技创新战略落地。 7月15日，德展健康（000813）公告，为了深入整合公司及所属公司的内外专家资源力量，充分发挥专 家团队科技创新决策外脑支持作用，提升公司科技创新质量，优化科技创新决策机制，公司董事会审议 同意将设立"科技创新发展中心"。 据公告披露，科技创新发展中心主要职责为聚焦国家健康领域政策动态，分析政策导向，提出与公司战 略适配的方案建议；遴选国内医药健康领域顶尖专家，组建高端智库专家库，为公司战 ...

Performance Forecast - The company expects a net loss for the period from January 1, 2025, to June 30, 2025, with an estimated loss of 25 million to 50 million yuan, compared to a profit of 10.15 million yuan in the same period last year [1] - The net profit attributable to shareholders is projected to decline by 346.24% to 592.48% compared to the previous year [1] - The basic earnings per share are expected to be a loss of 0.0117 to 0.0234 yuan per share, down from a profit of 0.0047 yuan per share last year [1] Reasons for Performance Change - The primary reason for the negative net profit is the impact of centralized procurement policies on the company's revenue, along with the fact that new business ventures are still in the development stage and have not yet contributed to profits [1]

Group 1 - The company held its 20th meeting of the 8th Supervisory Board on July 10, 2025, with 4 supervisors attending [1][2] - The meeting approved a proposal to amend the company's Articles of Association, changing the name of the shareholders' meeting to the shareholders' assembly and transferring the supervisory powers to the Board of Directors' Audit Committee [1][2] - The amendments will take effect upon approval by the shareholders' assembly, and the current Supervisory Board regulations will be abolished [1][2] Group 2 - The voting results for the proposal were unanimous, with 4 votes in favor, 0 against, and 0 abstentions [2] - The proposal will be submitted for further review at the shareholders' assembly [2] - The company has disclosed a comparison table of the amendments on its official information platform [2]

Meeting Information - The company will hold its first extraordinary general meeting of shareholders in 2025 on July 30, 2025, at 14:30 [1] - The meeting will include both on-site and online voting options, with specific time slots for each [1] Shareholder Rights - All ordinary shareholders registered by the close of trading on July 24, 2025, have the right to attend the meeting and can appoint proxies to vote on their behalf [2] - The meeting will also be attended by the company's directors, supervisors, senior management, and other required personnel [2] Agenda Items - The meeting will review several proposals, including amendments to the "Rules of Procedure for the Audit Committee of the Board" [3] - All proposals have been approved by the company's board and supervisory committee [3] Voting Procedures - Shareholders can vote through the Shenzhen Stock Exchange trading system and the internet voting system, with detailed procedures provided in the attachments [4][5] - Voting will be non-cumulative, meaning that if shareholders vote on both the total proposal and specific proposals, the first valid vote will be considered [5] Proxy Voting - A proxy authorization letter is required for representatives attending on behalf of shareholders, which must be submitted along with identification [4][8] - The authorization letter must specify the representative's name and the date of issuance [8]

Core Points - The company has revised its "Shareholders' Meeting Rules" to align with the latest legal regulations and its actual situation, changing the name from "Shareholders' General Meeting Rules" to "Shareholders' Meeting Rules" [1] - The revised rules clarify the responsibilities and powers of the shareholders' meeting, ensuring that it operates in accordance with the "Company Law" and other relevant regulations [1][2] - The rules now specify the procedures for convening, proposing, notifying, and holding shareholders' meetings, including the timelines for annual and extraordinary meetings [2][3] Group 1 - The company must hold an annual shareholders' meeting within six months after the end of the previous fiscal year, while extraordinary meetings can be called as needed [2][3] - If the company cannot convene a shareholders' meeting within the specified timeframe, it must report to the China Securities Regulatory Commission and the Shenzhen Stock Exchange [3] - The board of directors is required to convene the shareholders' meeting within the stipulated time and must provide written feedback on any proposals for extraordinary meetings from independent directors [3][4] Group 2 - Shareholders holding 10% or more of the company's shares can request the board to convene an extraordinary meeting, and the board must respond within 10 days [4][5] - If the board does not agree to convene the meeting, it must provide reasons and announce them [4][5] - The rules also allow the supervisory board or shareholders to convene meetings independently if the board fails to do so [5][6] Group 3 - The revised rules stipulate that shareholders can propose temporary proposals 10 days before the meeting, and the conveners must notify all shareholders of these proposals within 2 days [7][8] - All proposals must be fully disclosed in the meeting notifications to allow shareholders to make informed decisions [8][9] - The rules require that any election of directors or supervisors must provide detailed information about the candidates, including their backgrounds and any potential conflicts of interest [9][10] Group 4 - The company must hold the shareholders' meeting at its registered location or another location specified in its articles of association, ensuring that it is accessible to shareholders [10][11] - Shareholders can attend the meeting in person or through proxies, and each share carries one voting right [11][12] - The meeting must be presided over by a designated director or representative, and the minutes must accurately reflect the proceedings and decisions made [12][13] Group 5 - The rules emphasize that any resolutions passed at the shareholders' meeting must comply with legal and regulatory requirements, and any violations can be challenged in court [25][26] - The company is responsible for ensuring that the rights of minority investors are protected and that they can exercise their voting rights without obstruction [25][26] - The board of directors is tasked with executing the resolutions of the shareholders' meeting promptly to ensure the company's normal operations [26][27]

Core Viewpoint - Dezheng Health (000813) expects a net profit loss of 25 million to 50 million yuan in the first half of 2025, compared to a profit of 10.15 million yuan in the same period last year, representing a year-on-year decline of 346.24% to 592.48% [1] Financial Summary - The projected net profit loss for the first half of 2025 is between 25 million and 50 million yuan [1] - The profit for the same period last year was 10.15 million yuan [1] - The year-on-year decline in net profit is estimated to be between 346.24% and 592.48% [1]

1 德展大健康股份有限公司 《股东会议事规则》修订前后对照表 根据《公司法》《上市公司章程指引（2025 年修订）》等最新法律法规、规范 性文件的相关规定，结合公司实际情况，对《股东大会议事规则》进行修订。修 订后，公司《股东大会议事规则》更名为《股东会议事规则》。具体内容如下： | 修订前 | 修订后 | | --- | --- | | 股东大会议事规则 | 股东会议事规则 | | 第一条 为维护德展大健康股份有限 | | | 公司（以下简称"公司"）及公司股东的合 | 第一条 为维护德展大健康股份有限公 | | | 司（以下简称"公司"）及公司股东的合法权 | | 法权益，明确股东大会的职责权限，保证股 | 益，明确股东会的职责权限，保证股东会依 | | 东大会依法行使职权，根据《中华人民共和 | | | 国公司法》（以下简称"公司法"）《中华人 | 法行使职权，根据《中华人民共和国公司法》 | | | （以下简称"《公司法》"）、《中华人民共和国 | | 民共和国证券法》（以下简称"证券法"）《上 | 证券法》（以下简称"《证券法》"）、《上市公 | | 市公司治理准则》《上市公司股东大会规 | 司治理 ...